Cargando…
Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion
Here we report the case of an ALS patient found to carry both a novel heterozygous change (c.194G>A) within the spastin gene and a homozygous deletion of the SMN2 gene. The patient was started on valproic acid (VPA, 600 mg/die per os) considering the capacity of this drug of increasing survival m...
Autores principales: | Tremolizzo, Lucio, Sala, Gessica, Conti, Elisa, Rodriguez-Menendez, Virginia, Fogli, Antonella, Michelucci, Angela, Simi, Paolo, Penco, Silvana, Lunetta, Christian, Corbo, Massimo, Ferrarese, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124810/ https://www.ncbi.nlm.nih.gov/pubmed/25143843 http://dx.doi.org/10.1155/2014/216094 |
Ejemplares similares
-
Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes
por: Sala, Gessica, et al.
Publicado: (2019) -
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis
por: Conti, Elisa, et al.
Publicado: (2021) -
Spastin coordinates the recycling program
por: Short, Ben
Publicado: (2013) -
The Role of Spastin in Axon Biology
por: Costa, Ana Catarina, et al.
Publicado: (2022) -
A homozygous double mutation in SMN1: a complicated genetic diagnosis of SMA
por: Kirwin, Susan M, et al.
Publicado: (2013)